Inhibition of insulin-degrading enzyme in human neurons promotes amyloid-β deposition
Neuronal Signaling · 20.12.2023 · 7 (4)
DOI: 10.1042/ns20230016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuronal Signaling, online erschienen am 03.10.2023. Verfasst von Helen A Rowland und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neuroscience, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, M13 9PT, Manchester, U.K. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UKRI | Medical Research Council, UKRI | Biotechnology and Biological Sciences Research Council, Dr Donald Dean Fund for Dementia Research.
Abstract (Originalsprache)
Alzheimer’s disease (AD) is characterised by the aggregation and deposition of amyloid-β (Aβ) peptides in the human brain. In age-related late-onset AD, deficient degradation and clearance, rather than enhanced production, of Aβ contributes to disease pathology. In the present study, we assessed the contribution of the two key Aβ-degrading zinc metalloproteases, insulin-degrading enzyme (IDE) and neprilysin (NEP), to Aβ degradation in human induced pluripotent stem cell (iPSC)-derived cortical neurons. Using an Aβ fluorescence polarisation assay, inhibition of IDE but not of NEP, blocked the degradation of Aβ by human neurons. When the neurons were grown in a 3D extracellular matrix to visualise Aβ deposition, inhibition of IDE but not NEP, increased the number of Aβ deposits. The resulting Aβ deposits were stained with the conformation-dependent, anti-amyloid antibodies A11 and OC that recognise Aβ aggregates in the human AD brain. Inhibition of the Aβ-forming β-secretase prevented the formation of the IDE-inhibited Aβ deposits. These data indicate that inhibition of IDE in live human neurons grown in a 3D matrix increased the deposition of Aβ derived from the proteolytic cleavage of the amyloid precursor protein. This work has implications for strategies aimed at enhancing IDE activity to promote Aβ degradation in AD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Neuroscience, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, M13 9PT, Manchester, U.K.
- Geoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, Northern Care Alliance and University of Manchester, Manchester, U.K.
ORCID-Profile: Nigel M Hooper
Förderung
- UKRI | Medical Research Council
- UKRI | Biotechnology and Biological Sciences Research Council
- Dr Donald Dean Fund for Dementia Research
- University of Manchester
Zitieren
APA
Rowland, H. A., Moxon, S. R., Corbett, N. J., Hanson, K., Fisher, K., Kellett, K. A. B., & Hooper, N. M. (2023). Inhibition of insulin-degrading enzyme in human neurons promotes amyloid-β deposition. Neuronal Signaling, 7(4). https://doi.org/10.1042/ns20230016
Vancouver
Rowland HA, Moxon SR, Corbett NJ, Hanson K, Fisher K, Kellett KAB, et al. Inhibition of insulin-degrading enzyme in human neurons promotes amyloid-β deposition. Neuronal Signaling. 2023;7(4). doi:10.1042/ns20230016
BibTeX
@article{Rowland2023,
author = {Rowland, Helen A and Moxon, Samuel R and Corbett, Nicola J and Hanson, Kelsey and Fisher, Kate and Kellett, Katherine A B and Hooper, Nigel M},
title = {Inhibition of insulin-degrading enzyme in human neurons promotes amyloid-β deposition},
journal = {Neuronal Signaling},
year = {2023},
volume = {7},
number = {4},
doi = {10.1042/ns20230016}
}
EUVIMED